Neoadjuvant Anbenitamab Meets Primary Endpoint in Ph 3 HER2-Positive Breast Cancer Trial April 7, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to Evorpacept in Combination with Ziihera in HER2+ve Breast Cancer February 1, 2026
ENHERTU + Pertuzumab Type II Variation Application Validated in the EU in 1L HER2+ve Metastatic Breast Cancer January 25, 2026
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer January 18, 2026
Pidnarulex (CX-5461) – Enhertu combo to be evaluated in Ph 1b trial in HER2-positive and HER2-low solid tumors and breast cancer patients December 30, 2025
Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer December 30, 2025
Preliminary Analysis Shows 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 December 22, 2025
IND Application to Initiate a Ph 1 Trial of ABP-102/CT-P72 for HER2-positive Cancers submitted to the US FDA December 22, 2025
ENHERTU Plus Pertuzumab Approved in the US for Patients with 1L HER2 Positive Metastatic Breast Cancer December 22, 2025
Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer October 29, 2025
NMPA approves trastuzumab botidotin (A166) for patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapy October 18, 2025
TUKYSA Combination Significantly Improves PFS as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial October 16, 2025
Supplemental BLA for Adjuvant ENHERTU Followed by THP Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer October 8, 2025
Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Enhertu + pertuzumab granted Priority Review in the US as 1L treatment for patients with HER2-positive metastatic breast cancer September 30, 2025
Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies announced July 15, 2025
Ten-year APHINITY data show Perjeta-based regimen reduced the risk of death by 17% in people with HER2+ve early-stage breast cancer May 21, 2025
Enhertu recommended for approval in the EU by CHMP for patients with HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy March 4, 2025
Dragonfly Announces Clinical Collaboration Exploring Combinations of DF1001 HER-2 TriNKET® with Trodelvy® in two Cancer Indications February 26, 2024
Menarini Group and SciClone Pharmaceuticals to Develop and Commercialize ORSERDU® (Elacestrant) in China in Advanced or Metastatic Breast Cancer December 11, 2023
First Patient Enrolled in Ph 2 Study of BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu December 11, 2023
Kadcyla shows significant OS benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment December 11, 2023
